EP
MAZE

Essential Partners’s Maze Therapeutics MAZE Stock Holding History

Essential Partners’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209 Hold
7
– – ﹤0.01% 2630
2026
Q1 		$209 Hold
7
– – ﹤0.01% 2601
2025
Q4 		$290 Hold
7
– – ﹤0.01% 2348
2025
Q3 		$182 Hold
7
– – ﹤0.01% 2413
2025
Q2 		$86 Buy
+7
New +$73 ﹤0.01% 2088

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Essential Partners's MAZE Position: Q2 2026 in Review

Essential Partners held its Maze Therapeutics (MAZE) position steady in Q2 2026 at 7 shares worth $209. The position accounts for ﹤0.01% of the portfolio, ranked #2630.

Essential Partners first reported a position in MAZE in Q2 2025 and has held it in 5 quarters since. The position peaked at $290 in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Essential Partners held 7 shares of Maze Therapeutics worth $209 as of Q2 2026.
  • Essential Partners left its Maze Therapeutics share count unchanged in Q2 2026.
  • Maze Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2630 holding.
  • Essential Partners first reported a position in Maze Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Maze Therapeutics position peaked at $290 in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.